GRI Bio Earnings Call Transcripts
Fiscal Year 2026
-
GRI Bio highlighted positive phase 2A results for its lead IPF program, showing safety, biomarker improvements, and potential disease-modifying effects. Plans include advancing to phase 2B and filing an IND for a lupus program, with ongoing partnership discussions.
-
Stockholders approved both a reverse stock split amendment and a potential adjournment proposal, with voting results to be reported on Form 8-K within four business days. A quorum was established and stakeholders had an opportunity for Q&A.
Fiscal Year 2025
-
Lead program GRI-0621 is nearing Phase 2A data in IPF, with promising interim results and a robust biomarker strategy. GRI-0803 is set to enter clinical trials for lupus next year. The pipeline targets high unmet needs in fibrotic and autoimmune diseases, with strong preclinical and early clinical data supporting future growth.
-
GRI Bio is advancing GRI-0621, an NKT cell inhibitor, in a phase 2A IPF trial with interim data showing safety and early antifibrotic signals. Top-line results are expected in Q3, and the company is exploring additional pipeline assets targeting autoimmune diseases.
-
GRI-0621, a type I invariant NKT cell inhibitor, is in phase 2a trials for IPF, with interim and top-line data expected in Q2 and Q3. Early results show safety and an antifibrotic signal. The company is also advancing a pipeline targeting other NKT cell subsets.